---
title: "Uni-Bio Science Revamps Share Option Scheme Ahead of 2026 Expiry"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/283839554.md"
description: "Uni-Bio Science Group Ltd. plans to terminate its existing share option scheme from 2016, set to expire in September 2026, and replace it with a new scheme. The current scheme has 420,589,000 outstanding options and will stop new grants. The new scheme aims to reward eligible contributors through share-based incentives, pending shareholder and Stock Exchange approval. Uni-Bio operates in the biotechnology sector, focusing on healthcare products for the Greater China market."
datetime: "2026-04-23T12:38:54.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/283839554.md)
  - [en](https://longbridge.com/en/news/283839554.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/283839554.md)
---

# Uni-Bio Science Revamps Share Option Scheme Ahead of 2026 Expiry

### Claim 30% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Uni-Bio Science Group Ltd. ( (HK:0690) ) has shared an update.

Uni-Bio Science Group plans to terminate its existing share option scheme, which was adopted in 2016 and is due to expire in September 2026, and replace it with a new share option scheme. The current scheme has 420,589,000 outstanding options and will cease to allow new grants, prompting the board to refresh its equity incentive structure.

The proposed new scheme, to be adopted in line with Hong Kong Listing Rules, aims to continue rewarding eligible contributors to the group through share-based incentives. Its adoption is subject to shareholder approval at an extraordinary general meeting and the Stock Exchange’s approval for listing and dealing in new shares up to 10% of the company’s issued share capital at the time of the meeting.

**More about Uni-Bio Science Group Ltd.**

Uni-Bio Science Group Limited is a Cayman Islands-incorporated company listed on the Hong Kong Stock Exchange. The group operates in the biotechnology and life sciences sector through its subsidiaries, focusing on developing and commercialising healthcare-related products and technologies for the Greater China market and beyond.

**Average Trading Volume:** 5,845,799

**Technical Sentiment Signal:** Sell

**Current Market Cap:** HK$577.8M

### Related Stocks

- [UBX.US](https://longbridge.com/en/quote/UBX.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [00690.HK](https://longbridge.com/en/quote/00690.HK.md)

## Related News & Research

- [08:00 ETAvance Clinical Receives Frost & Sullivan's 2026 Global Company of the Year Recognition for Excellence in Biotech CRO Leadership](https://longbridge.com/en/news/286094661.md)
- [Dyadic International Q1 net loss narrows](https://longbridge.com/en/news/286311192.md)
- [MiNK Therapeutics' Q1 net loss narrows slightly](https://longbridge.com/en/news/286558132.md)
- [Wave Life Sciences posts positive RestorAATion-2 data; WVE-006 restores M-AAT, cuts Z-AAT, supports monthly dosing](https://longbridge.com/en/news/286818220.md)
- [Enanta Pharma's RSV Bet And Immunology Ambitions](https://longbridge.com/en/news/286895623.md)